CUSIP 746964105 · who reports it, how much, and how much it matters to them
16 of the 720 hedge fund managers we track reported shares of Q32 Bio Inc. (Nasdaq: QTTB) on Form 13F for 30 June 2026. Between them they reported USD 156m. The largest position belongs to Orbimed Advisors, at USD 53m. The manager with the most riding on it is Boxer Capital Management, where it is 3.0% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Orbimed Advisors1 fund on PPLI.com | USD 53m | 1.0% |
| 2 | Boxer Capital Management1 fund on PPLI.com | USD 40m | 3.0% |
| 3 | Ra Capital Management1 fund on PPLI.com | USD 30m | 0.3% |
| 4 | POINT72 Asset Management17 funds on PPLI.com | USD 15m | 0.0% |
| 5 | Logos Global Management1 fund on PPLI.com | USD 10m | 0.4% |
| 6 | Renaissance Technologies13 funds on PPLI.com | USD 2.3m | 0.0% |
| 7 | Boothbay Fund Management2 funds on PPLI.com | USD 1.7m | 0.0% |
| 8 | Citadel Advisors32 funds on PPLI.com | USD 1.5m | 0.0% |
| 9 | Marshall Wace LLP84 funds on PPLI.com | USD 854,000 | 0.0% |
| 10 | Two Sigma Investments35 funds on PPLI.com | USD 632,000 | 0.0% |
| 11 | Dafna Capital Management6 funds on PPLI.com | USD 419,000 | 0.1% |
| 12 | Squarepoint Ops7 funds on PPLI.com | USD 303,000 | 0.0% |
| 13 | Mangrove Partners Im1 fund on PPLI.com | USD 282,000 | 0.0% |
| 14 | Balyasny Asset Management25 funds on PPLI.com | USD 157,000 | 0.0% |
| 15 | Exoduspoint Capital Management7 funds on PPLI.com | USD 144,000 | 0.0% |
| 16 | Millennium Management6 funds on PPLI.com | USD 139,000 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Boxer Capital Management | USD 40m | 3.0% |
| 2 | Orbimed Advisors | USD 53m | 1.0% |
| 3 | Logos Global Management | USD 10m | 0.4% |
| 4 | Ra Capital Management | USD 30m | 0.3% |
| 5 | Dafna Capital Management | USD 419,000 | 0.1% |
| 6 | Boothbay Fund Management | USD 1.7m | 0.0% |
| 7 | Mangrove Partners Im | USD 282,000 | 0.0% |
| 8 | POINT72 Asset Management | USD 15m | 0.0% |
| 9 | Renaissance Technologies | USD 2.3m | 0.0% |
| 10 | Marshall Wace LLP | USD 854,000 | 0.0% |
Q32 Bio Inc. trades under the symbol QTTB on the Nasdaq. Its CUSIP, the code used on Form 13F, is 746964105.
16 of the 720 hedge fund managers PPLI.com tracks reported Q32 Bio Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Orbimed Advisors (USD 53m), Boxer Capital Management (USD 40m), Ra Capital Management (USD 30m), POINT72 Asset Management (USD 15m) and Logos Global Management (USD 10m).
16 managers in our coverage reported it, and between them they run 239 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Boxer Capital Management, where the position was 3.0% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Q32 Bio Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.